
@Pinanda76i
🇨🇦Account based in
About this account
- Account based in
- Canada
- Connected via
- Web
Account-level information from X, not a live location or the device used for a specific post.
Clinical Oncologist and Researcher at North East Cancer Centre, Health Sciences North. Science fan!
Greater Sudbury / Grand Sudbur
Joined June 2017
- Tweets135
- Following418
- Followers111
- Likes217
Dr. Chen Lee MBO management paradigm at ESMO Gynecological Cancers @StephanieLheur5 @NazlinJivraj
@myESMO
A great practical presentation on Mirvetuximab in patients with platinum resistant ovarian cancers by my dear colleague🌟 @AinhoaMada @myESMO
EUROCAN what a great example on what collaboration can achieve to improve management decisions for patients with rare gynecological cancers
@myESMO #ESMOgynecologicalcancers2024
instagram.com/p/C8eLUueNqG4/…
🌟🌟🌟Exceptional educational discussion this morning in ESMO GYNE @myESMO #Florence
The evolving la escape in endometrial cancer from staging to therapy.
FIGO 2023, ADCs are approaching 💉
cslide.ctimeetingtech.com/gy…
Luisa Bonilla retweeted
Congrats Ainhoa! 🎉👏Outstanding PhD brilliantly presented! It was a real pleasure and honour to co-direct your thesis! Looking forward to continue working together!
Very happy for defending my PhD today
⚪Grateful to my 🔝🔝 directors @StephanieLheur5 & @AnaOaknin and tutor @dvalcarcel
⚪Honoured to have @PerezFidal @CristinaSaura3 & @Esanzgarcia as an outstanding reviewer panel
Very impressive results! Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer | New England Journal of Medicine @NEJM nejm.org/doi/full/10.1056/NE…
Luisa Bonilla retweeted
📣 Do not miss this great e-Session on the newest data on DDR targeting agent @ESOncology
Join us for an insightful e-Session on "DNA damage response targeting agents" featuring expert Timothy Yap and Ilaria Colombo (@Ilaria_Colombo_) as discussant.
📅 Today, 18:15 CEST
Don't miss out ➡️ bit.ly/e-ESO
#ESOncology #oncology #oncologyeducation
Luisa Bonilla retweeted
Apply for the CRIS Cancer-Princess Margaret drug development fellowship @criscancer @pmcancercentre - great opportunity for those with interests in phase I trials and translational research criscancer.org/es/cris-princ…
Luisa Bonilla retweeted
Such an honor to be part of this great event! Thanks @myESMO for the opportunity.
The ESMO Summit Africa 2024 just wrapped up 📢 Three outstanding days together looking into 👇
✅ The most significant treatment advances presented at ESMO Congresses
✅ Current standard of care for key malignancies from local & international perspectives
ow.ly/CTBU50QAK5C
A refreshing reflection on how we need to be change cancer categorization to allow treatment access. But how are we going to get equity in molecular cancer testing?
@YvonneBombard
Forget lung, breast or prostate cancer: why tumour naming needs to change nature.com/articles/d41586-0…
Luisa Bonilla retweeted
New germline genetic testing guidelines: All women with breast cancer diagnosis under the age of 65 should be offered germline genetic testing. They don’t need to meet any additional criteria. Thank you @ASCO for the opportunity to draft these guidelines.
ascopubs.org/doi/full/10.120…
Luisa Bonilla retweeted
One of the most important trials presented and published in 2023
🌟🌟🌟 In DESTINY-PanTumor02, Trastuzumab deruxtecan showed durable responses across HER2-expressing solid tumors ➡️ brnw.ch/21wFvEs #gyncsm #hpbcsm #blcsm @MDAndersonNews
Luisa Bonilla retweeted
Correct! Anthracyclines were originally discovered in Italy approximately 70 years ago by a company named Farmitalia.
A member of the team went on expedition to Castel del Monte, in Puglia, in which soil he identified a strain of Streptomyces producing a substance with antitumoral proprieties: he called it “Daunomycin”, from the tribes of “Daunii” that used to live in Puglia during the Bronze Age.
The first trials with daunomycin were conducted at the NCI of Milan and at MSKCC, describing the first clinical responses. Meanwhile, the team at Farmitalia kept working on the molecule, developing an even more potent analogue.
They called it “Adriamycin”, from the Adriatic Sea that bathes the shores of Puglia, and that can be easily reached from Castel del Monte, where everything started.
More info here: journals.sagepub.com/doi/10.…
Luisa Bonilla retweeted
Happy to present at #ESMO23 the results of #MBOT the first app 📱 for Ambulatory Malignant Bowel Obstruction management in #gynecancer @pmcancercentre
Thanks to @ConquerCancerFd for making it possible through a #YIA grant – at Madrid, Spain
Luisa Bonilla retweeted
I❤️❤️being a thoracic oncologist: while our GI colleagues still struggle with folfox and folfiri 🥱we have numerous new exciting ⚡️& effective Tx 🔥 ADCs will soon be a part of our new routine so register to this webinar by @IASLC with @danieltanmd Ben Levy and Toni Wozniak
Antibody drug conjugates are novel agents developed for the treatment of a variety of cancers, including #lungcancer. In 2 weeks, this webinar will describe the mechanism of action of these agents, their current use & areas of development. Register: bit.ly/emergingADCSinLC #LCSM
Luisa Bonilla retweeted
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in HER2+ #CRC
@NatureComms
doi.org/10.1038/s41467-023-3…
👉ORR 45.3%, mPFS 6.9, mOS 15.5 and DoR 7.0 mo in IHC 3+/IHC 2+,ISH+
👉Pneumonitis 9.3%, TEAEs ≥3 65%
👉sig. activity independent of prior 🎯💊
@myESMO @OncoAlert
Every CRC patient should be HER2 tested🧪. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer | Nature Communications nature.com/articles/s41467-0…
Luisa Bonilla retweeted
I’m pretty certain I’m alive because I am white & was born into a middle class family in the US.
Dr Upal Basu Roy & I often say while I/everyone deserves quality care, it’s hard to balance when much of what we advocate for will only reach ppl like me ‘a person of privilege’ 😔
Dr Ji @WinshipAtEmory #ASCO23
🚨 New #Medicaid insurance after a #cancer diagnosis and non-continuous medicaid associated with ⬆️ mortality (HR >2) in children & AYA with blood cancers
Only 36% of Medicaid-insured children & AYA have continuous insurance coverage






































